Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences

Oncotarget

Volumn 5, Issue 20, 2014, Pages 9952-9965

  Kriegsmann, Mark ^a   Endris, Volker ^a,b   Wolf, Thomas ^a   Pfarr, Nicole ^a   Stenzinger, Albrecht ^a   Loibl, Sibylle ^c   Denkert, Carsten ^b,d   Schneeweiss, Andreas ^b   Budczies, Jan ^b,d   Sinn, Peter ^a   Weichert, Wilko ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c German Breast Group   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Immunohistochemistry; Mutation profiling; Next generation sequencing; Triple negative breast cancer

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; TRANSCRIPTION FACTOR GATA; UVOMORULIN;

ADULT; AGED; AMPLICON; ARTICLE; CANCER MORPHOLOGY; CANCER SURVIVAL; CELL CYCLE REGULATION; CHD1 GENE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EXOME; FOLLOW UP; GATA GENE; GENE; GENE DELETION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HERC1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; ONCOGENE MYC; OVERALL SURVIVAL; PIK3CA GENE; PTPRD GENE; RPS6KA1 GENE; SEMICONDUCTOR; TBX3 GENE; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; ULTRADEEP MULTIGENE SEQUENCING; CLASSIFICATION; ENZYMOLOGY; FEMALE; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; MULTIGENE FAMILY; MUTATION; NUCLEOTIDE SEQUENCE; SIGNAL TRANSDUCTION;

COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, P53; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOHISTOCHEMISTRY; MULTIGENE FAMILY; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84930455123     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2481     Document Type: Article

References (48)

1. WHO. (2014). World Health Organization: Breast Cancer burden. (http://www.who.int/cancer/detection/breastcancer/en/index1.html).
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, et al. Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-752.
3. Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR and Borresen-Dale AL. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC genomics. 2006; 7:127.
4. Paik S, Kim C and Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. The New England journal of medicine. 2008; 358(13):1409-1411.
5. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, Senn HJ and Panel M. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2013; 24(9):2206-2223.
6. Foulkes WD, Smith IE and Reis-Filho JS. Triple-negative breast cancer. The New England journal of medicine. 2010; 363(20):1938-1948.
7. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC and Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035):917-921.
8. Sanga S, Broom BM, Cristini V and Edgerton ME. Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family. BMC medical genomics. 2009; 2:59.
9. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X and Perou CM. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast cancer research: BCR. 2010; 12(5):R68.
10. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H and van de Vijver MJ. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast cancer research: BCR. 2007; 9(5):R65.
11. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y and Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of clinical investigation. 2011; 121(7):2750-2767.
12. Elsawaf Z, Sinn HP, Rom J, Bermejo JL, Schneeweiss A and Aulmann S. Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour. Breast. 2013; 22(5):986-992.
13. Poumpouridou N and Kroupis C. Hereditary breast cancer: beyond BRCA genetic analysis; PALB2 emerges. Clinical chemistry and laboratory medicine: CCLM/FESCC. 2012; 50(3):423-434.
14. Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sanchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gomez H, Horiuchi D, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer discovery. 2014; 4(2):232-245.
15. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61-70.
16. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, Bashashati A, Prentice LM, Khattra J, Burleigh A, Yap D, Bernard V, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012; 486(7403):395-399.
17. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, Yates LR, Papaemmanuil E, Beare D, Butler A, Cheverton A, Gamble J, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature [2012;] 486(7403):400-404.
18. Salto-Tellez M and de Castro DG. Next Generation Sequencing: A Change of Paradigm in Molecular Diagnostic Validation. The Journal of pathology. 2014.
19. Endris V, Penzel R, Warth A, Muckenhuber A, Schirmacher P, Stenzinger A and Weichert W. Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing. The Journal of molecular diagnostics: JMD. 2013; 15(6):765-775.
20. Turner N, Moretti E, Siclari O, Migliaccio I, Santarpia L, D'Incalci M, Piccolo S, Veronesi A, Zambelli A, Del Sal G and Di Leo A. Targeting triple negative breast cancer: is p53 the answer? Cancer treatment reviews. 2013; 39(5):541-550.
21. Tilch E, Seidens T, Cocciardi S, Reid LE, Byrne D, Simpson PT, Vargas AC, Cummings MC, Fox SB, Lakhani SR and Chenevix Trench G. Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women. Breast cancer research and treatment. 2014; 143(2):385-392.
22. Engebraaten O, Vollan HK and Borresen-Dale AL. Triple-negative breast cancer and the need for new therapeutic targets. The American journal of pathology. 2013; 183(4):1064-1074.
23. Santarpia L, Qi Y, Stemke-Hale K, Wang B, Young EJ, Booser DJ, Holmes FA, O'Shaughnessy J, Hellerstedt B, Pippen J, Vidaurre T, Gomez H, Valero V, Hortobagyi GN, Symmans WF, Bottai G, et al. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast cancer research and treatment. 2012; 134(1):333-343.
24. O'Toole SA, Beith JM, Millar EK, West R, McLean A, Cazet A, Swarbrick A and Oakes SR. Therapeutic targets in triple negative breast cancer. Journal of clinical pathology. 2013; 66(6):530-542.
25. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012; 486(7403):346-352.
26. Speers C, Tsimelzon A, Sexton K, Herrick AM, Gutierrez C, Culhane A, Quackenbush J, Hilsenbeck S, Chang J and Brown P. Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15(20):6327-6340.
27. Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, Goel N, Aronson AB, Li S, Ma CX, Ding L, Mardis ER and Ellis MJ. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer discovery. 2013; 3(2):224-237.
28. Baselga J. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. The oncologist. 2011; 16 Suppl 1:12-19.
29. Andre F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. The lancet oncology. 2014; 15(6):580-591.
30. MacConaill LE. Existing and emerging technologies for tumor genomic profiling. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31(15):1815-1824.
31. Adams JR, Xu K, Liu JC, Agamez NM, Loch AJ, Wong RG, Wang W, Wright KL, Lane TF, Zacksenhaus E and Egan SE. Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation. Cancer research. 2011; 71(7):2706-2717.
32. Saini KS, Loi S, de Azambuja E, Metzger-Filho O, Saini ML, Ignatiadis M, Dancey JE and Piccart-Gebhart MJ. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer treatment reviews. 2013; 39(8):935-946.
33. De Luca A, Maiello MR, D'Alessio A, Pergameno M and Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert opinion on therapeutic targets. 2012; 16 Suppl 2:S17-27.
34. Craig DW, O'Shaughnessy JA, Kiefer JA, Aldrich J, Sinari S, Moses TM, Wong S, Dinh J, Christoforides A, Blum JL, Aitelli CL, Osborne CR, Izatt T, Kurdoglu A, Baker A, Koeman J, et al. Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Molecular cancer therapeutics. 2013; 12(1):104-116.
35. Kolacinska A, Chalubinska J, Zawlik I, Szymanska B, Borowska-Garganisz E, Nowik M, Fendler W, Kubiak R, Pawlowska Z, Morawiec Z and Szemraj J. Apoptosis-, proliferation, immune function-, and drug resistance-related genes in ER positive, HER2 positive and triple negative breast cancer. Neoplasma. 2012; 59(4):424-432.
36. Abdel-Fatah TM, Perry C, Dickinson P, Ball G, Moseley P, Madhusudan S, Ellis IO and Chan SY. Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2013; 24(11):2801-2807.
37. Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO and Foulkes WD. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC cancer. 2007; 7:134.
38. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM and Nielsen TO. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14(5):1368-1376.
39. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M and Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2004; 10(16):5367-5374.
40. Bogina GS, Lunardi G, Marcolini L, Brunelli M, Bortesi L, Marconi M, Coati F, Valerio M, Guerriero M, Massocco A, Pegoraro MC and Zamboni G. P16 but not retinoblastoma expression is related to clinical outcome in no-special-type triple-negative breast carcinomas. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2014; 27(2):204-213.
41. Shan M, Zhang X, Liu X, Qin Y, Liu T, Liu Y, Wang J, Zhong Z, Zhang Y, Geng J and Pang D. P16 and p53 play distinct roles in different subtypes of breast cancer. PloS one. 2013; 8(10):e76408.
42. Subhawong AP, Subhawong T, Nassar H, Kouprina N, Begum S, Vang R, Westra WH and Argani P. Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. The American journal of surgical pathology. 2009; 33(2):163-175.
43. Boyle DP, McArt DG, Irwin G, Wilhelm-Benartzi CS, Lioe TF, Sebastian E, McQuaid S, Hamilton PW, James JA, Mullan PB, Catherwood MA, Harkin DP and Salto-Tellez M. The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer. Histopathology. 2014.
44. Filipits M, Nielsen TO, Rudas M, Greil R, Stoger H, Jakesz R, Bago-Horvath Z, Dietze O, Regitnig P, Gruber-Rossipal C, Muller-Holzner E, Singer CF, Mlineritsch B, Dubsky P, Bauernhofer T, Hubalek M, et al. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014; 20(5):1298-1305.
45. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Archives of pathology & laboratory medicine. 2010; 134(7):e48-72.
46. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31(31):3997-4013.
47. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G and Mesirov JP. Integrative genomics viewer. Nature biotechnology. 2011; 29(1):24-26.
48. Klambauer G, Schwarzbauer K, Mayr A, Clevert DA, Mitterecker A, Bodenhofer U and Hochreiter S. cn. MOPS: mixture of Poissons for discovering copy number variations in next-generation sequencing data with a low false discovery rate. Nucleic acids research. 2012; 40(9):e69.